Intas and IntegriMedical to launch India’s first needle-free injection system for IVF and gynaecology
Intas becomes the first and only company in India to offer IVF and gynecology therapies with needle-free injections
Intas becomes the first and only company in India to offer IVF and gynecology therapies with needle-free injections
Masitinib targets mast cells, which play a critical role in severe forms of SCD and its complications, including vaso-occlusive crises, acute chest syndrome, and pain
AFib is a progressive condition where timely intervention is critical to disease management and, ultimately, the patient's quality of life
TactiFlex, the world’s first catheter with a flexible tip and contact?force sensing, allows doctors to deliver energy precisely and safely.
Using a combination of blood and faecal samples, the service examines key biomarkers, including hereditary genetic status
Efdoralprin alfa, a recombinant human alpha-1 antitrypsin (AAT)-Fc fusion protein, showed superior efficacy to standard plasma-derived therapy in adults with AATD
Dr Reddy’s will pay Immutep US$ 20 million upfront and could deliver as much as US$ 349.5 million in regulatory and commercial milestones
HYMPAVZI’s safety profile was generally favorable
The technology is intended to support imaging-based training, protocol optimisation and surgical planning
Subscribe To Our Newsletter & Stay Updated